Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Victor Jimenez Zepeda
Observed name:
Victor Zepeda
Institution:
University of Calgary
Observed institution:
University of Calgary
OpenAlex ID:
A5130717044
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis
2026
·
Efstathios Kastritis
, Giovanni Palladini
, et al.
·
Blood
·
4
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026
·
Ashutosh D. Wechalekar
, Angela Dispenzieri
, et al.
·
Journal of Clinical Oncology
·
2
PA-349 Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light Chain Amyloidosis
2026
·
Julia Catini
, Ashu Wechalekar
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-400 Real-World Outcomes and Predictors of Bispecific Antibody Therapy Response in a Racially Diverse Multiple Myeloma Cohort
2026
·
Joshua D. Kassner
, Susan Karass
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026
·
Ashutosh Wechalekar
, Angela Dispenzieri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026
·
Ashutosh Wechalekar
, Angela Dispenzieri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026
·
Ashutosh Wechalekar
, Angela Dispenzieri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders
2026
·
Edward Koo
, Sarah Albert
, et al.
·
Blood Cancer Journal
PDF
Show more works
View as search
Works count:
8
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type
